Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma Journal Article
| Authors: | Hess, G.; Dreyling, M.; Oberic, L.; Gine, E.; Zinzani, P. L.; Linton, K.; Vilmar, A.; Jerkeman, M.; Chen, J. M. H.; Ohler, A.; Stilgenbauer, S.; Thieblemont, C.; Lambert, J.; Zilioli, V. R.; Sancho, J. M.; Jimenez-Ubieto, A.; Fischer, L.; Eyre, T. A.; Keeping, S.; Park, J. E.; Wu, J. J.; Nunes, A.; Reitan, J.; Wade, S. W.; Salles, G. |
| Article Title: | Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma |
| Abstract: | The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure. © 2023 Kite Pharma. Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; controlled study; aged; survival analysis; retrospective studies; major clinical study; overall survival; lenalidomide; prednisone; cisplatin; doxorubicin; gemcitabine; cancer radiotherapy; cytarabine; rituximab; follow up; bortezomib; mantle cell lymphoma; etoposide; cohort analysis; bendamustine; cyclophosphamide; dexamethasone; retrospective study; vinblastine; health care quality; bleomycin; chimeric antigen receptor; epirubicin; hazard ratio; oxaliplatin; adoptive immunotherapy; immunotherapy, adoptive; lymphoma, mantle-cell; non-hodgkin lymphoma; phosphatidylinositol 3 kinase inhibitor; standard of care; clinical outcome; ofatumumab; idelalisib; ibrutinib; humans; human; male; female; article; obinutuzumab; varlilumab; venetoclax; atezolizumab; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; ecog performance status; chimeric antigen receptor t-cell immunotherapy; car t-cell therapy; acalabrutinib; bruton tyrosine kinase inhibitor; umbralisib; indirect treatment comparison; receptors, chimeric antigen; brexucabtagene autoleucel; tinostamustine; mantle cell lymphoma international prognostic index |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 65 |
| Issue: | 1 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2024-01-01 |
| Start Page: | 14 |
| End Page: | 25 |
| Language: | English |
| DOI: | 10.1080/10428194.2023.2268228 |
| PUBMED: | 37840282 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
